Skip to main content

Table 2 Clinical features for the patients with/without anti-infective therapy on ICU admission (day 0)

From: Epidemiology and prognosis of anti-infective therapy in the ICU setting during acute pancreatitis: a cohort study

 

Missing data

AIT-free patients on day 0 n = 501

Patients receiving AIT on day 0 n = 359

p value

Male, n (%)

0/5

313 (62)

239 (68)

NS

Age, years, median [IQR]

3/4

56 [43–71]

60 [49–73]

< 0.01

Clinical presentation on admission

 Pain onset/ICU admission interval, days, median [IQR]

0

2 [1–4]

4 [1–11]

< 0.001

 Oliguria/anuria, n (%)

0

219 (44)

154 (43)

NS

 BISAP score, median [IQR]

16/18

1 [0–1]

2 [1–2]

< 0.001

 Balthazar score E, n (%)

0

293 (58)

200 (56)

NS

Severity criteria on admission

 SOFA score, median [IQR]

10/12

4 [2–6]

5 [3–7]

< 0.001

 Respiratory failure*, n (%)

0

109 (22)

137 (38)

< 0.001

 Cardiovascular failure*, n (%)

0

77 (15)

162 (45)

< 0.001

 Renal failure*, n (%)

0

90 (18)

53 (15)

NS

 Septic shock, n (%)

0

7 (1)

110 (31)

< 0.001

 Acute respiratory distress syndrome, n (%)

0

25 (5)

37 (10)

< 0.01

Therapeutic management on admission

 Vasoactive support, n (%)

0/1

80 (16)

165 (46)

< 0.001

 Mechanical ventilation, n (%)

1/5

95 (19)

130 (37)

< 0.001

 Fluid loading, n (%)

2/12

348 (70)

277 (80)

< 0.01

 Renal replacement therapy, n (%)

1/10

36 (7)

42 (12)

< 0.05

 Anti-infective therapy, n (%)

0

359 (100)

< 0.001

Main treatments between day > 0 and day 30

 Need for red blood cell transfusion, n (%)

0

110 (22)

116 (32)

< 0.001

 Number of days of mechanical ventilation

2/8

0 [0–9]

2 [0–10]

< 0.001

 Vasoactive support, n (%)

0/1

186 (37)

208 (58)

< 0.001

 Renal replacement therapy, n (%)

2/0

127 (25)

93 (26)

NS

 Duration of RRT, days, median [IQR]

6/9

5 [2–14]

5 [2–15]

NS

Main complications between day > 0 and day 30

 Acute respiratory distress syndrome, n (%)

0/2

142 (28)

99 (28)

NS

 Septic shock, n (%)

39/32

90 (19)

124 (38)

0.001

 Pancreatic necrosis, n (%)

13/17

339 (69)

218 (64)

NS

 Infected necrosis, n (%)

20/24

88 (18)

117 (35)

< 0.001

 Gastro-intestinal perforation, n (%)

20/24

27 (6)

27 (8)

NS

 Vascular thrombosis, n (%)

16/22

55 (11)

53 (16)

NS

 Acute mesenteric ischaemia, n (%)

18/22

52 (11)

36 (11)

NS

 Intra-abdominal collection, n (%)

14/18

127 (26)

152 (45)

< 0.001

 Abdominal compartment syndrome, n (%)

16/22

52 (11)

31 (9)

NS

 Haemorrhage, n (%)

16/21

53 (11)

47 (14)

NS

 Peritonitis, n (%)

19/23

29 (6)

59 (18)

< 0.001

 Cholangitis, n (%)

21/19

18 (4)

41 (12)

< 0.001

 Digestive fistula, n (%)

19/21

11 (2)

20 (6)

< 0.01

Clinical management between day > 0 and day 30

 Endoscopic necrosectomy, n (%)

3/5

89 (18)

87 (25)

< 0.05

 Surgical necrosectomy, n (%)

1/5

119 (24)

132 (37)

< 0.001

 Radiological drainage, n (%)

1/5

56 (11)

72 (20)

< 0.001

Duration of ICU stay, days, median [IQR]

0

6 [2–17]

8 [3–21]

< 0.05

ICU readmission n (%)

0/1

30 (6)

26 (7)

NS

Hospital mortality rate, n (%)

0

104 (21)

93 (26)

NS

Time to death, days, median [IQR]

0

3 [1–18]

7 [1–31]

NS

  1. NS non-significant, NA not applicable, AIT anti-infective therapy, ERCP endoscopic retrograde cholangiopancreatography
  2. *According to the definition of the SOFA score